Amivantamab

Medication

Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody.

Nº Q106957199 ★

Common · Knowledge

Amivantamab

Medication

Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody.

Last price

—

Floor price

—

7-day median

—

30-day sales

0

30-day range

—

In circulation

0

Price history

Show table
Datemedian LowHighsales

Sales history

Last sale
—
30-day average
—
30-day low
—
30-day high
—
Sales 7d
0
Sales 30d
0

No sales yet.

Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.

From Wikipedia

Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. The US Food and Drug Administration considers it to be a first-in-class medication.

Text: Wikipédia, CC BY-SA 4.0. · Image: Laboratoires Servier (CC BY-SA 3.0) ·

Related cards

View card

Confirmation